Thursday, June 19th, 2025
Stock Profile: INZY

Inozyme Pharma, Inc. (INZY)

Market: NASD | Currency: USD

Address: 321 Summer Street

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.




📈 Inozyme Pharma, Inc. Historical Chart






📊 Statistics





💰 Dividend History


No dividend history available.



📅 Earnings & EPS History for Inozyme Pharma, Inc.


DateReported EPS
2026-05-12 (estimated upcoming)-
2026-03-09 (estimated upcoming)-
2025-11-03 (estimated upcoming)-
2025-11-02 (estimated upcoming)-
2025-08-04 (estimated upcoming)-
2025-08-03 (estimated upcoming)-
2025-05-14-0.44
2025-05-08-
2025-05-07-
2025-05-05-
2025-05-04-
2025-03-10-0.41
2025-03-09-
2024-11-05-0.39
2024-08-06-0.44
2024-08-05-0.44
2024-05-07-0.38
2024-05-06-0.38
2024-03-12-0.33
2024-03-11-0.33
2023-11-07-0.29
2023-11-06-0.29
2023-08-08-0.35
2023-08-07-0.35
2023-05-09-0.4
2023-05-08-0.4
2023-03-22-0.42
2023-03-21-0.42
2022-11-10-0.38
2022-11-09-0.38
2022-08-15-0.38
2022-08-14-0.38
2022-05-10-0.71
2022-05-09-0.71
2022-03-15-0.79
2022-03-14-0.79
2021-11-09-0.6
2021-11-08-0.6
2021-08-11-0.53
2021-08-10-0.53
2021-05-12-0.47
2021-05-11-0.47
2021-03-25-1.01
2021-03-24-1.01
2020-11-12-1.55
2020-11-11-1.55
2020-09-03-7.57
2020-09-02-7.57
2020-07-24-
2020-07-23-




📰 Related News & Research


No related articles found for "inozyme pharma".